Treating Age-Related Macular Degeneration (AMD)

There is no cure, or treatment, for dry age-related macular degeneration (AMD) at this time. Individuals diagnosed with advanced wet AMD can receive injections of therapeutic drugs in the eye to slow the progression of vision loss. Patients that are able to receive therapeutic injections will seek treatment with their eye doctor.

Approximately ninety-five percent of AMD patients are diagnosed with dry AMD. Researchers at the Retina Foundation are working diligently to find treatments for these individuals. Funding for this research is a crucial part of discovering treatments. Our AMD research is supported by individuals, foundations, and pharmaceutical/biotechnology corporations.

Should you have any questions about clinical trials being conducted at the Retina Foundation, or should you wish to join a trial, please contact our AMD clinical research staff at amd@retinafoundation.org or 214.363.3911, ext. 400.

REQUEST AN APPOINTMENT

AMD CLINICAL STUDIES WE ARE CURRENTLY ENROLLING FOR:

Boston Image Reading Center
For detailed information go to clinicaltrials.gov/ct2/home: NCT#: 03688243
Research Coordinator: Abigail Christie
Phone: 214.363.3911, ext. 118
Study Title: Non Exudative Age-Related Macular Degeneration Imaged With Swept Source Optical Coherence Tomography

Genentech, Inc.
For detailed information go to clinicaltrials.gov/ct2/home: NCT#: 03972709
Research Coordinator: Renee Denlar
Phone: 214.363.3911, ext. 145
Study Title: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GALLEGO)

Gyroscope Therapeutics
For detailed information go to clinicaltrials.gov/ct2/home: NCT#: 03894020
Research Coordinator: Abigail Christie
Phone: 214.363.3911, ext. 118
Study Title: A Study of Disease Progression in Genetically Defined Subjects With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

National Eye Institute (NEI)
For detailed information go to clinicaltrials.gov/ct2/home: NCT#: 03092492
Research Coordinator: Renee Denlar
Phone: 214.363.3911, ext. 145
Study Title: AMD Ryan Initiative Study

Ionis Pharmaceuticals, Inc.
For detailed information go to clinicaltrials.gov/ct2/home: NCT#: 03815825
Research Coordinator: Kimberly Cummings
Phone: 214.363.3911, ext. 128
Study Title: A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)